| Bioactivity | Piritrexim (BW 301U) is a potent dihydrofolate reductase (DHFR) inhibitor against Pneumocystis carinii and Toxoplasma gondii, with IC50 values of 0.038 and 0.011 μM, respectively. Piritrexim can be used for acquired immune deficiency syndrome (AIDS) research. Piritrexim also is an anticancer agent[1]. |
| CAS | 72732-56-0 |
| Formula | C17H19N5O2 |
| Molar Mass | 325.37 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Rosowsky A, et al. 2,4-Diaminothieno[2,3-d]pyrimidine analogues of trimetrexate and piritrexim as potential inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase. J Med Chem. 1993 Oct 15;36(21):3103-12. [2]. Zink M, et al. Structural variations of piritrexim, a lipophilic inhibitor of human dihydrofolate reductase: synthesis, antitumor activity and molecular modeling investigations. Eur J Med Chem. 2004 Dec;39(12):1079-88. |
Piritrexim
CAS: 72732-56-0 F: C17H19N5O2 W: 325.37
Piritrexim (BW 301U) is a potent dihydrofolate reductase (DHFR) inhibitor against Pneumocystis carinii and Toxoplasma go
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.